491 related articles for article (PubMed ID: 33590521)
1. An Updated Economic Analysis of the Global Polio Eradication Initiative.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):393-406. PubMed ID: 33590521
[TBL] [Abstract][Full Text] [Related]
2. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of the global polio eradication initiative.
Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Linkins J; Sutter RW; Aylward RB; Thompson KM
Vaccine; 2010 Dec; 29(2):334-43. PubMed ID: 21029809
[TBL] [Abstract][Full Text] [Related]
4. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
[TBL] [Abstract][Full Text] [Related]
5. Projection of Costs of Polio Eradication Compared to Permanent Control.
Zimmermann M; Hagedorn B; Lyons H
J Infect Dis; 2020 Feb; 221(4):561-565. PubMed ID: 31565733
[TBL] [Abstract][Full Text] [Related]
6. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):229-247. PubMed ID: 32339327
[TBL] [Abstract][Full Text] [Related]
7. Polio Eradication and Endgame Plan - Victory within Grasp.
Patel M; Menning L; Bhatnagar P
Indian Pediatr; 2016 Aug; 53 Suppl 1():S28-S32. PubMed ID: 27771636
[TBL] [Abstract][Full Text] [Related]
8. A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.
Thompson KM; Kalkowska DA; Badizadegan K
Risk Anal; 2021 Feb; 41(2):376-386. PubMed ID: 33084153
[TBL] [Abstract][Full Text] [Related]
9. Intensified Local Resource Mobilization for the Polio Eradication Initiative: The Experience of World Health Organization in Nigeria During 2008-2015.
Yehualashet YG; Horton J; Mkanda P; Vaz RG; Afolabi O; Gashu SG; Banda R; O'Malley H; Nsubuga P
J Infect Dis; 2016 May; 213 Suppl 3(Suppl 3):S101-7. PubMed ID: 26912380
[TBL] [Abstract][Full Text] [Related]
10. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
Kalkowska DA; Voorman A; Pallansch MA; Wassilak SGF; Cochi SL; Badizadegan K; Thompson KM
Vaccine; 2023 Apr; 41 Suppl 1():A12-A18. PubMed ID: 33962838
[TBL] [Abstract][Full Text] [Related]
11. Modeling and Managing Poliovirus Risks: We are Where we are….
Thompson KM
Risk Anal; 2021 Feb; 41(2):223-228. PubMed ID: 33590520
[TBL] [Abstract][Full Text] [Related]
12. Strengthening the partnership between routine immunization and the global polio eradication initiative to achieve eradication and assure sustainability.
Abdelwahab J; Dietz V; Eggers R; Maher C; Olaniran M; Sandhu H; Vandelaer J
J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S498-503. PubMed ID: 25316872
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis of post-polio certification immunization policies.
Sangrujee N; Cáceres VM; Cochi SL
Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
[TBL] [Abstract][Full Text] [Related]
14. Emerging challenges to realizing global polio eradication and their solutions.
M A S
East Mediterr Health J; 2022 Jul; 28(7):515-520. PubMed ID: 35959667
[TBL] [Abstract][Full Text] [Related]
15. The risks, costs, and benefits of possible future global policies for managing polioviruses.
Thompson KM; Tebbens RJ; Pallansch MA; Kew OM; Sutter RW; Aylward RB; Watkins M; Gary HE; Alexander J; Jafari H; Cochi SL
Am J Public Health; 2008 Jul; 98(7):1322-30. PubMed ID: 18511720
[TBL] [Abstract][Full Text] [Related]
16. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
[TBL] [Abstract][Full Text] [Related]
17. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.
Thompson KM; Kalkowska DA
Expert Rev Vaccines; 2020 Jul; 19(7):661-686. PubMed ID: 32741232
[TBL] [Abstract][Full Text] [Related]
18. The Challenge of Global Poliomyelitis Eradication.
Garon JR; Cochi SL; Orenstein WA
Infect Dis Clin North Am; 2015 Dec; 29(4):651-65. PubMed ID: 26610419
[TBL] [Abstract][Full Text] [Related]
19. Contribution of Global Polio Eradication Initiative-Funded Personnel to the Strengthening of Routine Immunization Programs in the 10 Focus Countries of the Polio Eradication and Endgame Strategic Plan.
van den Ent MMVX; Swift RD; Anaokar S; Hegg LA; Eggers R; Cochi SL
J Infect Dis; 2017 Jul; 216(suppl_1):S244-S249. PubMed ID: 28838165
[TBL] [Abstract][Full Text] [Related]
20. Polio Endgame, Information Gaps Related to Vaccines and Immunity.
Ahmad M; Bahl S; Kunwar A
Indian Pediatr; 2016 Aug; 53 Suppl 1():S33-S37. PubMed ID: 27771637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
